Medication info
Ranpacapsule 15 mg (Lansoprazole granules)

Ranpacapsule 15 mg (Lansoprazole granules)

Prescription medicationHard capsuleOral
Ingredient · strength
Lansoprazole Granules›176.5mg / 1 capsule
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
A hard capsule with a white upper part and yellow lower part filled with white to light brown granules.
Packaging
28 capsules/bottle, 30 capsules/bottle, 90 capsules/bottle
Approval status
Active

MFDS item code 202201136 · Approved 2022.03.22 · Insurance code 694003780

Summary

Main use
Treatment and prevention of ulcers, eradication of Helicobacter pylori, and treatment of reflux disease and excessive gastric acid secretion
Who takes it
Adults · Children
Adult dose
This medicine should be taken before meals. For patients who have difficulty swallowing the medicine, open the capsule, mix the contents with a small amount (60 mL) of orange juice or tomato juice, and take immediately. To ensure that the full dose is taken, rinse the glass with twice or more the amount of juice and drink immediately. Do not chew or crush this medicine after opening the capsule. Short-term treatment of active duodenal ulcers: Administer lansoprazole 15 mg orally once daily for 4 weeks. Short-term treatment of active benign gastric ulcers: Administer lansoprazole 30 mg orally once daily for 8 weeks. Eradication of Helicobacter pylori to prevent recurrence of duodenal ulcers: Administer lansoprazole 30 mg with clarithromycin 250 ∼ 500 mg and amoxicillin 1,000 mg twice daily (every 12 hours) for 7 days. Treatment may be given for up to 14 days, if needed. Eradication of Helicobacter pylori to prevent recurrence of duodenal ulcers: Administer lansoprazole 30 mg with amoxicillin 1,000 mg 3 times daily (every 8 hours) for 14 days. Maintenance therapy after treatment of duodenal ulcers: Administer lansoprazole 15 mg orally once daily. The duration of comparative clinical trials did not exceed 12 months. Treatment of nonsteroidal anti-inflammatory drug-induced gastric ulcers: Administer lansoprazole 30 mg orally once daily for 8 weeks. The duration of comparative clinical trials did not exceed 8 weeks. Reduction of the risk of nonsteroidal anti-inflammatory drug-induced gastric ulcers: Administer lansoprazole 15 mg orally once daily for 12 weeks. The duration of comparative clinical trials did not exceed 12 weeks. Short-term treatment of symptoms associated with gastroesophageal reflux disease: Administer lansoprazole 15 mg orally once daily for 8 weeks. Short-term treatment of erosive esophagitis: Administer lansoprazole 30 mg orally once daily for 8 weeks. Maintenance therapy after treatment of erosive esophagitis: Administer lansoprazole 15 mg orally once daily. Pathological hypersecretory conditions, including Zollinger-Ellison syndrome: The dosage of lansoprazole for pathological hypersecretory conditions varies from patient to patient. In adults, treatment is usually started at 60 mg once daily. The dose should be adjusted according to the patient's needs and may be continued for as long as it is clinically effective. Doses of 90 mg per dose up to twice daily have been administered. If the daily dose exceeds 120 mg, it should be given in divided doses. Because clearance of this medicine is reduced in elderly patients, dose adjustment is necessary. Do not exceed a daily dose of 30 mg. Use with caution, including dose adjustment, in patients with hepatic impairment, as metabolism and excretion of this medicine may be delayed.
Child dose
Children and adolescents 12 ∼ 17 years: Short-term treatment of symptoms associated with non-erosive gastroesophageal reflux disease — 15 mg once daily for 8 weeks Children and adolescents 12 ∼ 17 years: Short-term treatment of erosive esophagitis — 30 mg once daily for 8 weeks Children 1 ∼ 11 years, 30 kg or less: Short-term treatment of symptoms associated with gastroesophageal reflux disease and erosive esophagitis — 15 mg once daily for 12 weeks Children 1 ∼ 11 years, over 30 kg: Short-term treatment of symptoms associated with gastroesophageal reflux disease and erosive esophagitis — 30 mg once daily for 12 weeks

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Treatment and prevention of ulcers, eradication of Helicobacter pylori, and treatment of reflux disease and excessive gastric acid secretion

  • Active duodenal ulcer
  • active benign gastric ulcer
  • recurrence of duodenal ulcer
  • NSAID-induced gastric ulcer
  • symptoms related to gastroesophageal reflux disease
  • erosive esophagitis
  • Zollinger-Ellison syndrome
  • pathological hypersecretion conditions.
View approved original text

This medication is used for the short-term treatment of active duodenal ulcers and active benign gastric ulcers. It is also effective in eradicating Helicobacter pylori to prevent recurrence of duodenal ulcers. Maintenance therapy after treatment can prevent recurrence of duodenal ulcers and erosive esophagitis, and it helps in the treatment of NSAID-induced gastric ulcers and reduces the risk of occurrence. Additionally, it is used for the short-term treatment of gastroesophageal reflux disease and erosive esophagitis, as well as pathological hypersecretion conditions such as Zollinger-Ellison syndrome. This medication is very effective in treating and preventing various gastrointestinal diseases.

How to take

Adult dose

This medicine should be taken before meals. For patients who have difficulty swallowing the medicine, open the capsule, mix the contents with a small amount (60 mL) of orange juice or tomato juice, and take immediately. To ensure that the full dose is taken, rinse the glass with twice or more the amount of juice and drink immediately. Do not chew or crush this medicine after opening the capsule. Short-term treatment of active duodenal ulcers: Administer lansoprazole 15 mg orally once daily for 4 weeks. Short-term treatment of active benign gastric ulcers: Administer lansoprazole 30 mg orally once daily for 8 weeks. Eradication of Helicobacter pylori to prevent recurrence of duodenal ulcers: Administer lansoprazole 30 mg with clarithromycin 250 ∼ 500 mg and amoxicillin 1,000 mg twice daily (every 12 hours) for 7 days. Treatment may be given for up to 14 days, if needed. Eradication of Helicobacter pylori to prevent recurrence of duodenal ulcers: Administer lansoprazole 30 mg with amoxicillin 1,000 mg 3 times daily (every 8 hours) for 14 days. Maintenance therapy after treatment of duodenal ulcers: Administer lansoprazole 15 mg orally once daily. The duration of comparative clinical trials did not exceed 12 months. Treatment of nonsteroidal anti-inflammatory drug-induced gastric ulcers: Administer lansoprazole 30 mg orally once daily for 8 weeks. The duration of comparative clinical trials did not exceed 8 weeks. Reduction of the risk of nonsteroidal anti-inflammatory drug-induced gastric ulcers: Administer lansoprazole 15 mg orally once daily for 12 weeks. The duration of comparative clinical trials did not exceed 12 weeks. Short-term treatment of symptoms associated with gastroesophageal reflux disease: Administer lansoprazole 15 mg orally once daily for 8 weeks. Short-term treatment of erosive esophagitis: Administer lansoprazole 30 mg orally once daily for 8 weeks. Maintenance therapy after treatment of erosive esophagitis: Administer lansoprazole 15 mg orally once daily. Pathological hypersecretory conditions, including Zollinger-Ellison syndrome: The dosage of lansoprazole for pathological hypersecretory conditions varies from patient to patient. In adults, treatment is usually started at 60 mg once daily. The dose should be adjusted according to the patient's needs and may be continued for as long as it is clinically effective. Doses of 90 mg per dose up to twice daily have been administered. If the daily dose exceeds 120 mg, it should be given in divided doses. Because clearance of this medicine is reduced in elderly patients, dose adjustment is necessary. Do not exceed a daily dose of 30 mg. Use with caution, including dose adjustment, in patients with hepatic impairment, as metabolism and excretion of this medicine may be delayed.

Child dose

Children and adolescents 12 ∼ 17 years: Short-term treatment of symptoms associated with non-erosive gastroesophageal reflux disease — 15 mg once daily for 8 weeks Children and adolescents 12 ∼ 17 years: Short-term treatment of erosive esophagitis — 30 mg once daily for 8 weeks Children 1 ∼ 11 years, 30 kg or less: Short-term treatment of symptoms associated with gastroesophageal reflux disease and erosive esophagitis — 15 mg once daily for 12 weeks Children 1 ∼ 11 years, over 30 kg: Short-term treatment of symptoms associated with gastroesophageal reflux disease and erosive esophagitis — 30 mg once daily for 12 weeks

Precautions

This medication should not be used in patients with specific allergic reactions. Special caution is needed for those who have hypersensitivity to this medication or its ingredients or who are allergic to penicillin or macrolide antibiotics. Pregnant women and patients with lactose intolerance should not take this medication. Patients with impaired liver or kidney function, elderly patients, nursing mothers, and children should be especially cautious when using this medication. If severe allergic reactions, blood abnormalities, liver dysfunction, or serious skin reactions occur during treatment, notify healthcare professionals immediately. Regular health check-ups are necessary during long-term treatment, particularly to monitor for vitamin B12 deficiency, increased fracture risk, and hypomagnesemia. Drug interactions may occur when taken with other medications, so inform healthcare professionals of all medications being taken and follow their instructions. The safety of this medication during pregnancy has not been established, and it is advisable to avoid use during nursing. There is limited experience with use in children, so caution is especially needed, and older adults should start at a lower dose. In case of overdose, seek appropriate treatment immediately; this medication is not removed by hemodialysis. Store this medication out of the reach of children and do not transfer it to another container. Dizziness or drowsiness may occur during treatment, so caution is needed when driving or operating machinery.

Side effects

Anaphylactic reaction, generalized rash, facial swelling, dyspnea, shock, pancytopenia, agranulocytosis, hemolytic anemia, neutropenia, thrombocytopenia, anemia, jaundice, elevated AST, elevated ALT, toxic liver dysfunction, toxic epidermal necrolysis, Stevens-Johnson syndrome, DRESS syndrome, interstitial pneumonia, interstitial nephritis, acute renal failure, membranous colitis, abdominal pain, diarrhea, headache, abdominal distension, allergic reaction, back pain, weakness, candidiasis, cancer, chills, chest pain, edema, fever, flu-like symptoms, halitosis, infection, fatigue, neck stiffness, pelvic pain, angina, arrhythmia, bradycardia, tachycardia, cerebrovascular accident, cerebral infarction, hypertension, hypotension, migraine, myocardial infarction, palpitations, vasodilation, syncope, asthma, bronchitis, increased cough, epistaxis, hemoptysis, hiccups, pneumonia, upper respiratory infection, laryngeal tumor, pulmonary fibrosis, pharyngitis, pleural disorders, respiratory disorders, rhinitis, sinusitis, wheezing, abnormal stool, enteritis, gastritis, gastrointestinal dysregulation, gastrointestinal diseases, gastrointestinal bleeding, loss of appetite, gastric stones, pyloric spasm, cholelithiasis, constipation, thirst, dry mouth, dyspepsia, dysphagia, belching, esophageal stricture, esophageal ulcer, esophagitis, fecal discoloration, abdominal distension, gastric nodules, gastric mucosal polyps, gastroenteritis, upper gastrointestinal bleeding, hematemesis, increased appetite, increased saliva, rectal bleeding, stomatitis, tongue disorders, glossitis, gingival bleeding, acute abdomen, colitis, vomiting, nausea, diarrhea, gastrointestinal candidiasis, rectal disorders, rectal bleeding, diabetes, goiter, hypothyroidism, anemia, bleeding, lymphadenopathy, vitamin deficiency, gout, hyperglycemia, hypoglycemia, dehydration, weight gain, weight loss, peripheral edema, bone disease, joint disease, leg cramps, arthritis, arthralgia, musculoskeletal pain, myalgia, myasthenia, ptosis, synovitis, agitation, amnesia, anxiety, apathy, confusion, depression, dizziness, syncope, hallucinations, unilateral paralysis, worsened hostility, decreased libido, increased libido, neurosis, sensory abnormalities, abnormal thoughts, convulsions, dementia, depersonalization, diplopia, hyperactivity, hypertonia, sensory loss, insomnia, sleep disorders, drowsiness, tremors, acne, hair loss, pruritus, rash, urticaria, contact dermatitis, dry skin, nail disorders, skin cancer, skin diseases, sweating, abnormal vision, amblyopia, blepharitis, cataract, conjunctivitis, dry eyes, ear diseases, eye diseases, glaucoma, abnormal olfaction, photophobia, retinal degeneration, loss of taste, blurred vision, deafness, eye pain, otitis media, taste disturbance, tinnitus, visual field narrowing, urination disorders, renal pain, penile disorders, testicular disorders, urethral pain, polyuria, frequency of urination, residual urine, menstrual irregularities, chest tenderness, chest expansion, gynecomastia, diabetes, hematuria, erectile dysfunction, renal stones, hepatotoxicity, pancreatitis, taste disturbance, aplastic anemia, leukocytopenia, thrombocytopenic purpura, eosinophilia, hypomagnesemia, Clostridium difficile associated diarrhea, fracture, myositis, erythema multiforme, acute generalized exanthematous pustulosis, speech disorder, urinary retention, elevated ALP, elevated LDH, elevated γ-GTP, weakness, hyponatremia, elevated total cholesterol, decreased total cholesterol, tongue paralysis, lip paralysis, limb paralysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. The storage temperature should be maintained between 1°C and 30°C room temperature. This helps maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

A hard capsule with a white upper part and yellow lower part filled with white to light brown granules.

Package unit

28 capsules/bottle, 30 capsules/bottle, 90 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.